adjuvant 6 cycles of docetaxel and cyclophosphamide or 3 cycles of cyclophosphamide/epirubicin/fluorouracil followed by 3 cycles of docetaxel versus 4 cycles of epirubicin and cyclophosphamide followed by weekly paclitaxel in operable breast cancer (master)

Conditions: Primary Breast Cancer

Summary: we aimed to evaluate the noninferiority of a short-term anthracycline-free chemotherapy (tc, six cycles of docetaxel and cyclophosphamide) or a short-term anthracycline-based chemotherapy (cef-t, three cycles of cyclophosphamide/epirubicin/fluorouracil followed by three cycles of docetaxel) to a standard anthracycline/taxane-containing chemotherapy (ec-p, epirubicin and cyclophosphamide for four cycles followed by paclitaxel for twelve weeks) in operable breast cancer.

it was initiated as an adjuvant chemotherapy trial in 2010 to test noninferiority of an anthracycline-free short-term regimen (t75c600 x 6 \[tc\] once every 3 weeks) or a short-term regimen (c500e100f500 x 3 once every 3 weeks followed by t100 x 3 every 3 weeks \[cef-t\]) compared with a standard long-term anthracycline-containing regimen (e90c600 x 4 once every 3 weeks followed by p80 x 12 once every week \[ec-p\]). patients were randomly assigned (1:1:1) to each arm after completing surgical excision of primary tumor. trastuzumab was administered in combination with chemotherapy to patients with her2-positive breast cancer and sustained monotherapy as per the current guidelines.

Eligibility criteria:
inclusion criteria: * female patients, age at diagnosis 18 - 75 years * histological confirmed unilateral primary invasive carcinoma of the breast * adequate surgical treatment with complete resection of the tumor (r0) and resection of \> or = 10 axillary nodes or sln in clinically n0 patients * node positive disease or node negative disease with at least one other risk factor (tumor size \> or = 2 cm, grade \> or = ii) * no evidence for distant metastasis (m0) after conventional staging * performance status ecog \< or = 1 * the patient must be accessible for treatment and follow-up * lvef\> 50% * negative pregnancy test (urine or serum) within 7 days prior to randomization in premenopausal patients * leucocytes \> or = 4 x 10\^9/l * platelets \> or = 100 x 10\^9/l * haemoglobin \> or = 9 g/dl * total bilirubin \< or = 1.5 unl * asat (sgot) and alat (sgpt) \< or = 2.5 unl * creatinine \< 175 mmol/l (2 mg/dl) exclusion criteria: 1. has received neoadjuvant therapy (include chemotherapy, targeted therapy, radiotherapy or endocrine therapy）; 2. has bilateral breast cancer; 3. has previous history of additional malignancy, with the exception of adequately treated basal cell carcinoma and cervical carcinoma in situ. 4. has metastic (stage 4) breast cancer; 5. has any \>t4 lesion (uicc1987) (with skin involvement, mass adhesion and fixation, and inflammatory breast cancer); 6. is pregnant, is breast feeding women, or women of childbearing age who cannot practice effective contraceptives; 7. patients participating in other clinical trials at the same time; 8. has severe organ dysfunction (cardiopulmonary liver and kidney) insufficiency, left ventricular ejection fraction (lvef) \ 150/90mmgh, myocardial infarction, or cerebral blood vessel); diabetic patients with poor blood glucose control; patients with severe hypertension; 9. has known allergy to taxane and excipients; 10. has severe or uncontrolled infection.